Psychopharmacology of ADHD in pediatrics: Current advances and issues

Neuropsychiatric Disease and Treatment

Volumn 5, Issue 1, 2009, Pages 171-181

  Greydanus, Donald E ^a,b   Nazeer, Ahsan ^a   Patel, Dilip R ^a  

^a MICHIGAN STATE UNIVERSITY   (United States)

^b MICHIGAN STATE UNIVERSITY   (United States)

Author keywords

ADHD; Alpha 2 agonists; Amphetamine; Antidepressants; Methylphenidate; Norepinephrine reuptake inhibitors

Indexed keywords

ALPHA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; AMFEBUTAMONE; AMITRIPTYLINE; AMPHETAMINE; ANTIDEPRESSANT AGENT; ATOMOXETINE; CLONIDINE; DESIPRAMINE; DEXAMPHETAMINE; DEXMETHYLPHENIDATE; ETHOSUXIMIDE; GUANFACINE; IMIPRAMINE; LISDEXAMFETAMINE; METHAMPHETAMINE; METHYLPHENIDATE; MODAFINIL; MONOAMINE OXIDASE INHIBITOR; NORADRENALIN UPTAKE INHIBITOR; NORTRIPTYLINE; PAROXETINE; PEMOLINE MAGNESIUM; PHENOBARBITAL; PHENYTOIN; PSYCHOSTIMULANT AGENT; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; SPANSULE; TRICYCLIC ANTIDEPRESSANT AGENT; UNCLASSIFIED DRUG; UNINDEXED DRUG; VENLAFAXINE;

ABDOMINAL PAIN; ACCOMMODATION PARALYSIS; AGITATION; ANOREXIA; ANTICHOLINERGIC SYNDROME; ANXIETY; APPLICATION SITE DERMATITIS; APPLICATION SITE IRRITATION; ATRIOVENTRICULAR BLOCK; ATTENTION DEFICIT DISORDER; ATTENTION DISTURBANCE; BEDTIME DOSAGE; BLOOD DYSCRASIA; BLURRED VISION; CHILD PSYCHIATRY; CONFUSION; CONSTIPATION; DECREASED APPETITE; DELIRIUM; DENTAL CARIES; DEPRESSION; DIZZINESS; DOSE RESPONSE; DROWSINESS; DRUG ABSORPTION; DRUG COMPETITION; DRUG CONTRAINDICATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG METABOLISM; DRUG OVERDOSE; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; DYSPEPSIA; DYSPHORIA; FATIGUE; GASTROINTESTINAL SYMPTOM; GILLES DE LA TOURETTE SYNDROME; GROWTH RETARDATION; HEART ARRHYTHMIA; HEART PALPITATION; HUMAN; HYPERACTIVITY; HYPERTENSION; HYPOSALIVATION; HYPOTENSION; INSOMNIA; IRRITABILITY; LIVER FAILURE; MANIA; MICTURITION DISORDER; MOOD CHANGE; MORNING DOSAGE; MYDRIASIS; NAUSEA; NERVOUSNESS; OBSTRUCTIVE JAUNDICE; OCULAR PRURITUS; ORTHOSTATIC HYPOTENSION; PERIPHERAL NEUROPATHY; PERSEVERATION; PERSONALITY; PRIAPISM; PSYCHOPHARMACOTHERAPY; PSYCHOSIS; PSYCHOSOCIAL WITHDRAWAL; QRS COMPLEX; QT PROLONGATION; RECOMMENDED DRUG DOSE; RESPIRATORY FAILURE; RESTLESSNESS; REVIEW; SEDATION; SEIZURE; SEXUAL DYSFUNCTION; SIDE EFFECT; SINGLE DRUG DOSE; SINUS TACHYCARDIA; SUDDEN DEATH; TACHYCARDIA; TIC; TREMOR; URINE RETENTION; VOMITING; WEIGHT GAIN; WEIGHT REDUCTION; XEROSTOMIA;

EID: 70449699759     PISSN: 11766328     EISSN: 11782021     Source Type: Journal    
DOI: 10.2147/ndt.s4075     Document Type: Review

References (75)

1. Greydanus DE, Pratt HD, Patel DR. Attention deficit hyperactivity disorder across the lifespan. Dis A Month. 2007;53(2):65-132.
2. Mayes R, Bagwell C, Erkulwater J. Medicating Children: ADHD and Pediatric Mental Health. Cambridge, Massachusetts: Harvard University Press; 2009.
3. Barkley RA. Attention-deficit/hyperactivity disorder. Sci Am. 1998;66-71.
4. Soileau EJ. Medications with adolescents with attention-deficit/ hyperactivity disorder. Adolesc Med. 2008;19:254-267.
5. Wolraich ML, Wibbelsman CJ, Brown TE, et al. Attention deficit/hyperactivity disorder among adolescents. Pediatrics. 2005;115:1734.
6. Staufer WB, Greydanus DE. Attention-deficit/hyperactivity disorder: Psychopharmacology for college students. Pediatric Clin North Am. 2005;52:71-84. (Pubitemid 40340933)
7. Biederman J, Faraone SC. Attention-deficit hyperactivity disorder. Lancet. 2005;367:237-248.
8. Robin A, Schubiner H, Coleman WL, eds. ADHD/learning disorders. Adolesc Med. 2008;19(2):209-356.
9. Epstein JN, Langberg JM, Lichtenstein PK, et al. Community-wide intervention to improve the attention-deficit/hyperactivity disorder assessment and treatment practices of community physicians. Pediatrics. 2008;122:19-27.
10. Mayes R, Rafalovich A. Suffer the restless children: the evolution of ADHD and paediatric stimulant use: 1900-1980. Hist Psychiatry. 2007;18(72 Pt 4):435-457.
11. Greydanus DE, Sloane MA, Rappley MD. Psychopharmacology of ADHD in adolescents. Adolesc Med. 2002;13:599-624.
12. Greydanus DE, Pratt HD, Sloane MA, et al. Attention-deficit/hyperactivity disorder in children and adolescents: Interventions for a complex costly clinical conundrum. Pediatr Clin North Am. 2003;50:1049-1092.
13. Hammerness P, Surman C, Miller K. Update on adult ADHD. Curr Neurol. Neurosci Rep. 2008;8:849-859.
14. Greydanus DE, Calles JL, Patel DR. Pediatric and Adolescent Psychopharmacology. Cambridge, England: Cambridge University Press; 2008.
15. Pierce D, Dixon CM, Wigal SB, et al. Pharmacokinetics of methylphenidate transdermal system (MTS): results from a classroom study. J Child Adolesc Psychopharmacol. 2008;18:355-364.
16. Patrick KC, Straughn AB, Perkins JS, González MA. Evolution of stimulants to treat ADHD: transdermal methylphenidate. Hum Psychopharmacol. 2009;24(1):1-17.
17. Greydanus DE. Pharmacologic treatment of attention-deficit/hyperactivity disorder. Indian J Pediatrics. 2005;72:27-34.
18. Greydanus DE, Pratt HD. ADHD in children and adolescents. In: Greydanus DE, Patel DR, Pratt HD, eds. Behavioral pediatrics, 2nd ed. New York: iUniverse Publishers; 2006.
19. Silva RR, Munix R, Pestreich L, et al. Dexmethylphenidate extended release capsules in children with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2008;47:199-208. (Pubitemid 351158788)
20. Solanto MV, Arnsten AFT, Castellanos FX. The Neuroscience of stimulant drug action in ADHD. In: Solanto MV, Arnsten AFT, Castellanos FX, eds. Stimulant drugs and ADHD. London: Oxford Univ Press, 2001. p. 355-379.
21. Zito JM, Safer DJ, dosReis S, et al. Psychotropic practice patterns for youth. A 10-year perspective. Arch Pediatr Adolesc Med. 2003;157:17-25.
22. Cox ER, Halloran DR, Homan SM, et al. Trends in the prevalence of chronic medication use in children: 2002-2005. Pediatrics. 2008;122:e1053-e1061.
23. Volkow ND, Fowler JS, Wang G, Ding Y, Gatley SJ. Mechanism of action of methylphenidate: insights from PET imaging studies. J Atten Disord. 2002;6(Suppl 1):S31-S43. (Pubitemid 44850815)
24. Tourette's Syndrome Study Group. Treatment of ADHD in children with tics: a randomized controlled trial. Neurology. 2002;58(4):527-536.
25. Patel DR, Greydanus DE: Neurological conditions and disability in adolescents. Intl J Disabil Hum Dev. 2008;7(3):279-282.
26. Jankovic J. Tourette's syndrome. N Engl J Med. 2001;345:1184-1192.
27. Perrin JM, Friedman RA, Knilans TK, et al. Cardiovascular monitoring and stimulant drugs for attention deficit/hyperactivity disorder. Pediatrics. 2008;122:451-453.
28. Vetter VL, Elia J, Erickson C, et al. Cardiovascular monitoring of children and adolescents with heart disease receiving stimulant drugs. A scientific statement from the American Heart Association Council on Cardiovascular Disease in the Young, Congenital Cardiac Defects Committee and the Council on Cardiovascular Nursing. Circulation. 2008;117:2407-2423. (Pubitemid 351653546)
29. Fone KCF, Nutt DJ. Stimulants: use and abuse in the treatment of attention deficit hyperactivity disorder. Curr Opin Pharmacol. 2005;5:87-93. (Pubitemid 40124540)
30. Wilens TE, Gignac M, Swezey A, et al. Characteristics of adolescents and young adults with ADHD who divert or misuse their prescribed medications. J Am Acad Child Adolesc Psychiatry. 2006;45:408-414. (Pubitemid 43675545)
31. Wilens TE, Faraone SV, Biederman J, et al. Does stimulant therapy of attention-deficit/hyperactivity disorder beget later substance abuse? A meta-analytic review of the literature. Pediatrics. 2003;111:179-185. (Pubitemid 36071051)
32. Greydanus DE, Patel DR. The adolescent and substance abuse: Current concepts. Curr Probl Pediatr Adolesc Health Care. 2005;35(3):78-98. (Pubitemid 40277223)
33. Bramstedt KA. Caffeine use by children: quest for enhancement. Subst Use Misuse. 2007;42:1237-1251.
34. Gehricke JG, Loughlin SE, Whalen CK, et al. Smoking to self-mediate attentional and emotional dysfunction. Nicotine Tob Res. 2007;9(Suppl 4):S523-S536.
35. Bradley C. The behavior of children receiving benzedrine. Am J Psychiatry. 1937;577-585.
36. Lisdexafetamine dimesylate (Vyvanse) for ADHD. Med Lett. 2007;49:58-59.
37. Lopez FA, Ginsberg LD, Arnold V. Effect of lisdexamfetamine dimethylate on parent-rated measures in children aged 6-12 years with attention-deficit hyperactivity disorder: a secondary analysis. Post grad Med. 2008;120:89-102.
38. http:www.fda.gov/medwatch/safety/2005/safety05.htm#Strattera.
39. Spencer T, Biederman J, Wilens T, et al. Effectiveness and tolerability of atomoxetine in adults with attention-deficit hyperactivity disorder. Am J Psychiatry. 1998;155:693-695. (Pubitemid 28225414)
40. Michelson D, Allen AJ, Busner J, et al. Once-daily atomoxetine treatment for children and adolescents with ADHD: A randomized, placebo-controlled study. Am J Psychiatry. 2002;159:1896-1901.
41. Atomoxetine (Strattera) for ADHD. Med Lett. 2003;45:11-12.
42. Allen AJ, Spencer TJ, Heiligenstein JH, et al. Safety and efficacy of atomoxetine for AHDH in two double-blind, placebo-controlled trials. Biol Psychiatry. 2001;49(Suppl 8):32S-33S.
43. Biedermann J, Melmed RD, Patel A. Guanfacine extended release for Pediatric Attention deficit/hyperactivity disorder. Pediatrics. 2008;121:e73-e84.
44. Biederman J, Melmed RD, Patel A, et al. A randomized, double-blind, placebo-controlled study of guanfacine extended release in children and adolescents with ADHD. Pediatrics. 2008;121:e73-e84.
45. Varley C. Sudden death of a child treated with imipramine. J Child Adolesc Psychopharmacol. 2000;10:321-325. (Pubitemid 32103908)
46. Varley CK. Sudden death related to selected tricyclic antidepressants in children: Epidemiology, mechanisms and clinical implications. Paediatr Drugs. 2001;3:613-627.
47. Pliszka SR, Greenhill LL, Crismon ML, et al. The Texas Children's Medication Algorithm Project: Report of the Texas Consensus Conference Panel on medication treatment of childhood attention-deficit/hyperactivity disorder. Part I. J Am Acad Child Adolesc Psychiatry. 2001;39:908-919. (Pubitemid 30429924)
48. Daviss WB. Buproprion for adolescents with attention-deficit/ hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2001;40:307-314.
49. Wilkes S. Bupropion. Drugs Today. 2006;42(10):671-681.
50. Findling RL, Greenhill LL, McNamara NK, et al. Venlafaxine in the treatment of children and adolescents with attention deficit hyperactivity disorder. J Child Adolesc Psychopharmacol. 2007;17:433-445. (Pubitemid 47417772)
51. Turner DC, Clark L, Dowson J, et al. Modafinil improves cognition and response inhibition in adult attention-deficit/hyperactivity disorder. Biol Psychiatry. 2004;55:1031-1040. (Pubitemid 38581919)
52. López FA. ADHD: New pharmacologic treatments on the horizon. J Dev Behav Pediatr. 2006;27:410-416.
53. Biederman J, Pliszka SR. Modafanil improves symptoms of attention-deficit hyperactivity disorder across subtypes in children and adolescents. J Pediatr. 2008;152:394-399. (Pubitemid 351231891)
54. Ballon JS, Feifel D. A systemic review of modafanil: Potential clinical uses and mechanism of action. J Clin Psychiatr. 2006;67:554-566. (Pubitemid 43764232)
55. Kumar R. Approved and investigational uses of modafanil: An evidence-based review. Drugs. 2008;68:1803-1839.
56. Stein MA, McGough JJ. The pharmacogenomic era: promise for personalizing ADHD therapy. Child Adolesc Psychiatry Clin N Amer. 2008;17:475-490.
57. Swanson JM, Hechtman L. Using long-acting stimulants: does it change ADHD treatment outcome? Can Child Adolesc Psychiatr Rev. 2005;14(Suppl 1):2-3.
58. Greydanus DE. Metilfenidato: Ventajas de metifenidato de liberacion immediata sobre las formulaciones de metifenidato de liberacion prolongada. Euromedice. 2007;2-3.
59. Danysz W. CX-516 Cortex Pharmaceuticals. Curr Opin Invest Drugs. 2002;3:1081-1088.
60. Weisler RA. Emerging drugs for ADHD. Expert Opin Emerg Drugs. 2007;12:423-434.
61. Levin ED. Nicotinic receptor subtypes and cognitive function. Neurol Biol. 2002;53:633-646.
62. Adler LA, Chua HC. Management of ADHD in adults. J Clin Psychiatr. 2002;63(Suppl 12):29-35.
63. Konofal E, Arnuuf I, Lecendreaux M, Mouren MC. Ropinirole in a child with attention-deficit hyperactivity disorder and restless legs syndrome. Pediatr Neurol. 2005;30:350-351. (Pubitemid 40615344)
64. Finding RL. Evolution of the treatment for attention-deficit hyperactivity disorder in children: a review. Clin Ther. 2008;30:942-951.
65. Karroum E, Konofal E, Arnuuf I. Restless legs syndrome. Rev Neurol. 2008;164:701-721.
66. Findling RL, Short EJ, Leskovec T, et al. Aripiprazole in children with ADHD. J Child Adolesc Psychopharmacol. 2008;18:347-354.
67. Findling RL. Atypical antipsychotic treatment of disruptive behavior disorders in children and adolescents. J Clin Psychiatry. 2008;69(Suppl 4):9-14.
68. Toren P, Ratner S, Weizman A, et al. Reboxetine maintenance treatment in children with ADHD: A long term follow-up study. J Child Adolesc Psychopharmacol. 2007;17:803-812.
69. A new long-acting methylphenidate (Concerta). Med Lett. 2000;42:80-81.
70. Another long-acting methylphenidate (Metadate CD). Med Lett. 2001;43:83-84.
71. Dexmethylphenidate (Focalin) for ADHD. Med Lett. 2002;44:45-46.
72. Pliszka S. AACAP Work Group on Quality Issues. Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/ hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2007;46:894-921.
73. Hechtman L, Greenfield B. Long-term use of stimulants in children with attention deficit hyperactivity disorder: safety, efficacy, and long-term outcome. Paediatr Drugs. 2003;5:787-794. (Pubitemid 38030604)
74. Lerner M, Wigal T. Long-term safety of stimulant medications used to treat children with ADHD. Pediatr Ann. 2008;37:37-45. (Pubitemid 351299661)
75. Calles JL. ADHD in children and adolescents. In: Greydanus DE, Patel DR, Pratt HD, eds. Behavioral Pediatrics, 3rd ed. New York: Nova Science Publishers; 2009.